Prothena Corp PLC (PRTA)
47.07
-1.00 (-2.08%)
USD |
NASDAQ |
Mar 24, 16:00
48.01
+0.94 (+2.00%)
After-Hours: 20:00
Prothena Cash from Financing (TTM): 241.46M for Dec. 31, 2022
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2022 | 241.46M |
September 30, 2022 | 22.46M |
June 30, 2022 | 91.35M |
March 31, 2022 | 110.34M |
December 31, 2021 | 190.33M |
September 30, 2021 | 188.56M |
June 30, 2021 | 101.61M |
March 31, 2021 | 81.39M |
December 31, 2020 | 0.215M |
September 30, 2020 | 0.228M |
June 30, 2020 | 0.164M |
March 31, 2020 | 0.374M |
December 31, 2019 | 0.228M |
September 30, 2019 | -1.089M |
June 30, 2019 | -2.064M |
March 31, 2019 | -3.135M |
December 31, 2018 | 40.04M |
September 30, 2018 | 42.81M |
June 30, 2018 | 46.39M |
March 31, 2018 | 48.72M |
December 31, 2017 | 165.40M |
Date | Value |
---|---|
September 30, 2017 | 183.24M |
June 30, 2017 | 184.88M |
March 31, 2017 | 184.19M |
December 31, 2016 | 153.29M |
September 30, 2016 | 133.58M |
June 30, 2016 | 131.99M |
March 31, 2016 | 264.92M |
December 31, 2015 | 136.99M |
September 30, 2015 | 137.38M |
June 30, 2015 | 149.40M |
March 31, 2015 | 118.60M |
December 31, 2014 | 118.08M |
September 30, 2014 | 202.75M |
June 30, 2014 | 187.96M |
March 31, 2014 | 85.04M |
December 31, 2013 | 84.45M |
September 30, 2013 | 141.32M |
June 30, 2013 | 148.99M |
March 31, 2013 | 159.39M |
December 31, 2012 | 168.23M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-3.135M
Minimum
Mar 2019
241.46M
Maximum
Dec 2022
60.02M
Average
41.43M
Median
Cash from Financing (TTM) Benchmarks
Mallinckrodt PLC | -- |
Jazz Pharmaceuticals PLC | -529.49M |
Nabriva Therapeutics PLC | 4.648M |
Iterum Therapeutics PLC | -1.818M |
GH Research PLC | -- |